Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression
Ricardo C Ferreira, Xaquin Castro Dopico, João J Oliveira, Daniel B Rainbow, Jennie H Yang, Dominik Trzupek, Sarah A Todd, Mhairi McNeill, Maristella Steri, Valeria Orrù, Edoardo Fiorillo, Daniel J M Crouch, Marcin L Pekalski, Francesco Cucca, Tim I Tree, Tim J Vyse, Linda S Wicker, John A Todd, Ricardo C Ferreira, Xaquin Castro Dopico, João J Oliveira, Daniel B Rainbow, Jennie H Yang, Dominik Trzupek, Sarah A Todd, Mhairi McNeill, Maristella Steri, Valeria Orrù, Edoardo Fiorillo, Daniel J M Crouch, Marcin L Pekalski, Francesco Cucca, Tim I Tree, Tim J Vyse, Linda S Wicker, John A Todd
Abstract
In systemic lupus erythematosus (SLE), perturbed immunoregulation underpins a pathogenic imbalance between regulatory and effector CD4+ T-cell activity. However, to date, the characterization of the CD4+ regulatory T cell (Treg) compartment in SLE has yielded conflicting results. Here we show that patients have an increased frequency of CD4+FOXP3+ cells in circulation owing to a specific expansion of thymically-derived FOXP3+HELIOS+ Tregs with a demethylated FOXP3 Treg-specific demethylated region. We found that the Treg expansion was strongly associated with markers of recent immune activation, including PD-1, plasma concentrations of IL-2 and the type I interferon biomarker soluble SIGLEC-1. Since the expression of the negative T-cell signaling molecule PTPN22 is increased and a marker of poor prognosis in SLE, we tested the influence of its missense risk allele Trp620 (rs2476601C>T) on Treg frequency. Trp620 was reproducibly associated with increased frequencies of thymically-derived Tregs in blood, and increased PD-1 expression on both Tregs and effector T cells (Teffs). Our results support the hypothesis that FOXP3+ Tregs are increased in SLE patients as a consequence of a compensatory mechanism in an attempt to regulate pathogenic autoreactive Teff activity. We suggest that restoration of IL-2-mediated homeostatic regulation of FOXP3+ Tregs by IL-2 administration could prevent disease flares rather than treating at the height of a disease flare. Moreover, stimulation of PD-1 with specific agonists, perhaps in combination with low-dose IL-2, could be an effective therapeutic strategy in autoimmune disease and in other immune disorders.
Keywords: FOXP3; PD-1; PTPN22 Arg620Trp; autoimmunity; immunotherapy; regulatory T cells (Tregs); systemic lupus erythematosus (SLE); type I interferon.
Copyright © 2019 Ferreira, Castro Dopico, Oliveira, Rainbow, Yang, Trzupek, Todd, McNeill, Steri, Orrù, Fiorillo, Crouch, Pekalski, Cucca, Tree, Vyse, Wicker and Todd.
Figures
References
- Tsokos GC. Systemic lupus erythematosus. N Engl J Med. (2011) 365:2110–21. 10.1056/NEJMra1100359
- Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. . Systemic lupus erythematosus. Nat Rev Dis Prim. (2016) 2:16039. 10.1038/nrdp.2016.39
- Kammer GM. Altered regulation of IL-2 production in systemic lupus erythematosus: an evolving paradigm. J Clin Invest. (2005) 115:836–40. 10.1172/JCI24791
- Lieberman LA, Tsokos GC. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J Biomed Biotechnol. (2010) 2010:740619. 10.1155/2010/740619
- Langefeld CD, Ainsworth HC, Graham DSC, Kelly JA, Comeau ME, Marion MC, et al. . Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. (2017) 8:16021. 10.1038/ncomms16021
- Onengut-Gumuscu S, Chen W-M, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et al. . Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. (2015) 47:381–6. 10.1038/ng.3245
- Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. (2009) 30:899–911. 10.1016/j.immuni.2009.03.019
- Kim O, Klaus T. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. (2014) 45:344–55. 10.1002/eji.201344280
- La Cava A. Tregs in SLE: an update. Curr Rheumatol Rep. (2018) 20:6. 10.1007/s11926-018-0714-8
- Wing JB, Tanaka A, Sakaguchi S. Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. (2019) 50:302–16. 10.1016/j.immuni.2019.01.020
- Ferreira RC, Simons HZ, Thompson WS, Rainbow DB, Yang X, Cutler AJ, et al. . Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity. J Autoimmun. (2017) 84:75–86. 10.1016/j.jaut.2017.07.009
- Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. (2007) 178:2579–88. 10.4049/jimmunol.178.4.2579
- Bonelli M, Savitskaya A, Steiner C-W, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+CD25–Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol. (2009) 182:1689–95. 10.4049/jimmunol.182.3.1689
- Suen J-L, Li H-T, Jong Y-J, Chiang B-L, Yen J-H. Altered homeostasis of CD4+ FoxP3+ regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology. (2009) 127:196–205. 10.1111/j.1365-2567.2008.02937.x
- Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, et al. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs Involves IL-6–Mediated Signaling. Sci Transl Med. (2013) 5:170ra15 10.1126/scitranslmed.3004970
- Stanford SM, Bottini N. PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol. (2014) 10:602–11. 10.1038/nrrheum.2014.109
- McKinney EF, Lyons PA, Carr EJ, Hollis JL, Jayne DRW, Willcocks LC, et al. . A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med. (2010) 16:586–91. 10.1038/nm.2130
- Ivashkiv LB. PTPN22 in autoimmunity: different cell and different way. Immunity. (2013) 39:91–3. 10.1016/j.immuni.2013.07.007
- Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, et al. . The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity. (2013) 39:111–22. 10.1016/j.immuni.2013.06.013
- Vang T, Congia M, Macis MD, Musumeci L, Orrú V, Zavattari P, et al. . Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. (2005) 37:1317–9. 10.1038/ng1673
- Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, Meng X, et al. . The autoimmune disease–associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet. (2011) 43:902–7. 10.1038/ng.904
- Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, et al. . Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. (2015) 74:791–2. 10.1136/annrheumdis-2014-206506
- von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. (2016) 75:1407–15. 10.1136/annrheumdis-2015-207776
- He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. . Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med. (2016) 22:991–3. 10.1038/nm.4148
- Thompson WS, Pekalski ML, Simons HZ, Smyth DJ, Castro-Dopico X, Guo H, et al. . Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol. (2014) 177:571–85. 10.1111/cei.12362
- Rainbow DB, Yang X, Burren O, Pekalski ML, Smyth DJ, Klarqvist MDR, et al. . Epigenetic analysis of regulatory T cells using multiplex bisulfite sequencing. Eur J Immunol. (2015) 45:3200–3. 10.1002/eji.201545646
- Oliveira J, Karrar S, Rainbow D, Pinder C, Clarke P, Rubio Garcia A, et al. . The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Res Ther. (2018) 20:152. 10.1186/s13075-018-1649-1
- Ferreira RC, Rainbow DB, Rubio García A, Pekalski ML, Porter L, Oliveira JJ, et al. . Human IL-6RhiTIGIT– CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and display a distinct Th17 profile. Clin Immunol. (2017) 179:25–39. 10.1016/j.clim.2017.03.002
- Trzupek D, Dunstan M, Cutler AJ, Lee M, Godfrey L, Aschenbrenner D, et al. Simultaneous mRNA and protein quantification at the single-cell level delineates trajectories of CD4+ T-cell differentiation. bioRxiv. (2019) 706275 10.1101/706275
- Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. . Comprehensive integration of single-cell data. Cell. (2019) 177:1888–902.e21. 10.1016/j.cell.2019.05.031
- Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, et al. . MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. (2015) 16:278. 10.1186/s13059-015-0844-5
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. (2007) 81:559–75. 10.1086/519795
- Kim H-J, Barnitz RA, Kreslavsky T, Brown FD, Moffett H, Lemieux ME, et al. . Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science. (2015) 350:334–9. 10.1126/science.aad0616
- Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. bioRxiv. (2018) 447367 10.1101/447367
- Ferreira RC, Rainbow DB, Rubio García A, Pekalski ML, Porter L, Oliveira JJ, et al. . In-depth immunophenotyping of IL-6R on the human peripheral regulatory T cell (Treg) compartment. Data Br. (2017) 12:676–91. 10.1016/j.dib.2017.04.043
- Alexander T, Sattler A, Templin L, Kohler S, Groß C, Meisel A, et al. . Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis. (2013) 72:1549–58. 10.1136/annrheumdis-2012-202216
- Golding A, Hasni S, Illei G, Shevach EM. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum. (2013) 65:2898–906. 10.1002/art.38119
- Todd JA, Evangelou M, Cutler AJ, Pekalski ML, Walker NM, Stevens HE, et al. . Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. PLoS Med. (2016) 13:e1002139. 10.1371/journal.pmed.1002139
- Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, et al. . CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells. J Exp Med. (2006) 203:1701–11. 10.1084/jem.20060772
- Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med. (2014) 211:961–74. 10.1084/jem.20131556
- Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. . Interferon-α suppresses cAMP to disarm human regulatory T cells. Cancer Res. (2013) 73:5647–56. 10.1158/0008-5472.CAN-12-3788
- Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-α-producing antigen-presenting cells. Arthritis Rheum. (2008) 58:801–12. 10.1002/art.23268
- Golding A, Rosen A, Petri M, Akhter E, Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology. (2010) 131:107–17. 10.1111/j.1365-2567.2010.03280.x
- Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther. (2010) 12:S5. 10.1186/ar2886
- Feng H, Yin J, Han Y-P, Zhou X-Y, Chen S, Yang L, et al. . Sustained changes of Treg and Th17 cells during interferon-α therapy in patients with chronic hepatitis B. Viral Immunol. (2015) 28:412–7. 10.1089/vim.2015.0024
- Gómez-Martín D, Díaz-Zamudio M, Crispín JC, Alcocer-Varela J. Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. Autoimmun Rev. (2009) 9:34–9. 10.1016/j.autrev.2009.02.035
- Alcocer-Varela J, Alarcón-Segovia D. Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematocus. Rheumatol Int. (1995) 15:57–63. 10.1007/BF00262709
- Huang YP, Miescher PA, Zubler RH. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol. (1986) 137:3515–20.
- Giang S, La Cava A. Regulatory T cells in SLE: biology and use in treatment. Curr Rheumatol Rep. (2016) 18:67. 10.1007/s11926-016-0616-6
- Mizui M, Tsokos GC. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. Front Immunol. (2018) 9:786. 10.3389/fimmu.2018.00786
- Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. . Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. (2011) 365:2067–77. 10.1056/NEJMoa1105143
- Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. . Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. (2016) 69:376–86. 10.1002/art.39962
- Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. . Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. (2016) 75:1909–16. 10.1136/annrheumdis-2015-208562
- Paluch C, Santos AM, Anzilotti C, Cornall RJ, Davis SJ. Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol. (2018) 9:2306. 10.3389/fimmu.2018.02306
- Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, et al. PD-1 modulates regulatory T cell homeostasis during low-dose IL-2 therapy. Blood. (2017) 129:2186–97. 10.1182/blood-2016-09-741629
- Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt FA, Liniany LP, Knight D, et al. . PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains Foxp3 transcription factor stability in induced regulatory T cells. Immunity. (2018) 49:247–63.e7. 10.1016/j.immuni.2018.05.006
Source: PubMed